Dornase alfa for cystic fibrosis
Connie Yang, Mark Montgomery
Abstract
Dornase alfa is currently used as a mucolytic to treat pulmonary disease (the major cause of morbidity and mortality) in cystic fibrosis. It reduces mucus viscosity in the lungs, promoting improved clearance of secretions. This is an update of a previously published review.
Topics & Concepts
MedicineCystic fibrosisPlaceboHypertonic salineInternal medicineAdverse effectClinical trialMeta-analysisRandomized controlled trialPhysical therapyIntensive care medicinePathologyAlternative medicineCystic Fibrosis Research AdvancesNeonatal Respiratory Health ResearchTracheal and airway disorders